Current treatments

An open label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin and dexamethasone in newly diagnosed myeloma. Nishihori T et al. Eur J Haematol. 2015 Jan 20. doi: 10.1111/ejh.12509. [Epub ahead of print]. A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myelomanot eligible for or who deferred autologous stem cell transplantation.…

Details

Amgen submits applications in Europe and the US for the approval of Kyprolis® as a treatment for myeloma

Amgen and its subsidiary, Onyx Pharmaceuticals Inc., have announced the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for Kyprolis (carfilzomib), seeking its approval as a treatment for relapsed myeloma patients who have received at least one prior treatment. In addition, a supplemental New Drug Application (sNDA) has been submitted…

Details